Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases

Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singh R, Pervin S, Lee S, Kuo A, Grijalva V, David J, Vergnes L, Reddy ST
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Follistatin Browning Obesity Metabolic profiling Metabolic Diseases Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/205fa0d3ae934c8c9884377911147ff2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:205fa0d3ae934c8c9884377911147ff2
record_format	dspace
spelling	oai:doaj.org-article:205fa0d3ae934c8c9884377911147ff22021-12-02T04:55:03ZMetabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases1178-7007https://doaj.org/article/205fa0d3ae934c8c9884377911147ff22018-03-01T00:00:00Zhttps://www.dovepress.com/metabolic-profiling-of-follistatin-overexpression-a-novel-therapeutic--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; 3The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; 4Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, CT, USA; 5Department of Biology, California State University Dominguez Hills, CA, USA; 6Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA; 7Department of Comparative Medicine, Pfizer Inc, San Diego, CA, USA; 8Department of Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells.Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention. Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQSingh RPervin SLee SKuo AGrijalva VDavid JVergnes LReddy STDove Medical PressarticleFollistatinBrowningObesityMetabolic profilingMetabolic DiseasesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 11, Pp 65-84 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Follistatin Browning Obesity Metabolic profiling Metabolic Diseases Specialties of internal medicine RC581-951
spellingShingle	Follistatin Browning Obesity Metabolic profiling Metabolic Diseases Specialties of internal medicine RC581-951 Singh R Pervin S Lee S Kuo A Grijalva V David J Vergnes L Reddy ST Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
description	Rajan Singh,1,2 Shehla Pervin,1,2 Se-Jin Lee,3,4 Alan Kuo,5 Victor Grijalva,6 John David,7 Laurent Vergnes,8 Srinivasa T Reddy1,6 1Department of Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, CA, USA; 2Division of Endocrinology and Metabolism, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA; 3The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; 4Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, CT, USA; 5Department of Biology, California State University Dominguez Hills, CA, USA; 6Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA, USA; 7Department of Comparative Medicine, Pfizer Inc, San Diego, CA, USA; 8Department of Human Genetics, UCLA School of Medicine, Los Angeles, CA, USA Background: Follistatin (Fst) promotes brown adipocyte characteristics in adipose tissues.Methods: Abdominal fat volume (CT scan), glucose clearance (GTT test), and metabolomics analysis (mass spectrometry) of adipose tissues from Fst transgenic (Fst-Tg) and wild type (WT) control mice were analyzed. Oxygen consumption (Seahorse Analyzer) and lipidomics (gas chromatography) was analyzed in 3T3-L1 cells.Results: Fst-Tg mice show significant decrease in abdominal fat content, increased glucose clearance, improved plasma lipid profiles and significant changes in several conventional metabolites compared to the WT mice. Furthermore, overexpression of Fst in 3T3-L1 cells resulted in up regulation of key brown/beige markers and changes in lipidomics profiles. Conclusion: Fst modulates key factors involved in promoting metabolic syndrome and could be used for therapeutic intervention. Keywords: follistatin, transgenic, adipocyte, fibroblast growth factor 21, AdipoQ
format	article
author	Singh R Pervin S Lee S Kuo A Grijalva V David J Vergnes L Reddy ST
author_facet	Singh R Pervin S Lee S Kuo A Grijalva V David J Vergnes L Reddy ST
author_sort	Singh R
title	Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_short	Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_full	Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_fullStr	Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_full_unstemmed	Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
title_sort	metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/205fa0d3ae934c8c9884377911147ff2
work_keys_str_mv	AT singhr metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT pervins metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT lees metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT kuoa metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT grijalvav metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT davidj metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT vergnesl metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases AT reddyst metabolicprofilingoffollistatinoverexpressionanoveltherapeuticstrategyformetabolicdiseases
_version_	1718400995777576960

Metabolic profiling of follistatin overexpression: a novel therapeutic strategy for metabolic diseases

Ejemplares similares